Acurx Pharmaceuticals LLC Market Cap ($4.38 Million)
Market Cap & Net Worth: Acurx Pharmaceuticals LLC (ACXP)
Acurx Pharmaceuticals LLC market cap. Acurx Pharmaceuticals LLC (NASDAQ:ACXP) has a market capitalization of $4.38 Million ($4.38 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28764 globally and #5913 in its home market, demonstrating a -5.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acurx Pharmaceuticals LLC's stock price $1.02 by its total outstanding shares 4297738 (4.30 Million). Also see ACXP cash flow conversion for how efficiently the company converts equity into cash flow.
Acurx Pharmaceuticals LLC Market Cap History (2021–2026)
Acurx Pharmaceuticals LLC market cap history from 2021 to 2026. Data shows change from $18.57 Million to $4.38 Million (-31.72% CAGR). Check current stock price of Acurx Pharmaceuticals LLC for real-time trading data and today's change.
Index Memberships
Acurx Pharmaceuticals LLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #827 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2648 of 3165 |
Weight: Acurx Pharmaceuticals LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Acurx Pharmaceuticals LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acurx Pharmaceuticals LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ACXP year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACXP by Market Capitalization
Companies near Acurx Pharmaceuticals LLC in the global market cap rankings as of November 4, 2026. Also see ACXP current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Acurx Pharmaceuticals LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Acurx Pharmaceuticals LLC (2021–2026)
Market capitalization of Acurx Pharmaceuticals LLC from 2021 to today. Between 2021 and today, Acurx Pharmaceuticals LLC's market cap moved from $18.57 Million to $ 4.38 Million, with a yearly change of -31.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.38 Million | -59.04% |
| 2025 | $10.70 Million | +205.90% |
| 2024 | $3.50 Million | -78.75% |
| 2023 | $16.46 Million | -3.77% |
| 2022 | $17.10 Million | -7.89% |
| 2021 | $18.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Acurx Pharmaceuticals LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.38 Million USD |
| MoneyControl | $4.38 Million USD |
| MarketWatch | $4.38 Million USD |
| marketcap.company | $4.38 Million USD |
| Reuters | $4.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more